年度報告2022
2022年度報告
InnoCare Pharma Limited
諾誠健華醫藥有限公司
InnoCare Pharma Limited
諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司）股份代號：
9969
2022
┃
AD
ALLAMLAQP4 IgG4
ASH
BBBT
BBiogenBiogen Inc.BIIB
BTDBTKBTKCD20BCD20MS4A1BCDCCDENMPA
┃
CLLCNSL
9969
DLBCLBDLTEULARFGFRFL
GMP
┃
IBDICP-105ICP-192ICP-022iDMCIL-2–2IL-5–5IL-12–12IL-23–23IND
IRCITKTITPiwNHLJAK
┃
MCDB(DLBCL)MYD88L265P
CD79BMCDMCLB
MSMZL
NDAMMOSDNMPA
NRDLNTRKFGFR(FGFR)TRKPD
┃
PK
R/Rr/rR-CHOPRICE
264,648.217
SC
0.000002
SHP2RASSLESLLSRISLE
┃
TT
TBNKTDCCTTRKTYK22UC
U.S.FDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII, LLCWM
┃
Ogier Global (Cayman) Limited89 Nexus WayCamana BayGrand CaymanKY1-9009Cayman IslandsOgier Global (Cayman) Limited89 Nexus WayCamana BayGrand CaymanKY1-9009Cayman Islands
1712-1716
9969www.Innocarepharma.com
┃
BTBT
MSII12BTKII12Gd+T180QD92.1%(p=0.0006)SLEIIa
SLESRI–4EULAR
CDESLEIIbITPIIPoC50x10
L
736.4%33125040%156
ICP-332ICP-3322TYK2T
IIPK/PDJAK-2AEADII
┃
ICP-488ICP-488TYK2TYK2JH2IL-23IL12IIFNICP-488
ISADMAD
ICP-248ICP-490ICP-B02TafasitamabNHLMM
BDLBCLNHL?
?BTK565.9
214.7164%
CSCO? NMPAMZL
NDA? CLL/SLLIII? MCLII
NDA? –1PD-1
EHA
┃
NHLDLBCL? MCDBDLBCLIII
R-CHOPR-CHOP
R-CHOPMCD DLBCLASCO14CRR75%
66.67%
ICP-B04TafasitamabCD19Minjuvi
?? TafasitamabDLBCL
ASCTDLBCLTafasitamabCSCOASCTDLBCL? TafasitamabNMPA
ASCTBDLBCLTafasitamabDLBCLTafasitamabDLBCL
ICP-B02 (CM355)
? ICP-B02CD20xCD3I
ICP-B02BICP-B02SCINDCDEMMICP-490? ICP-490
INDCDEI
┃
ICP-248? ICP-248B2BCL-2BCL-2
ICP-248INDCDE
I
ICP-192ICP-723ICP-192 (Gunagratinib)
ASCO-GIGunagratinibCCAIIaICP-192GunagratinibFGFR2
CCAFGFR(52.9%)CCAICP-192I/II
ICP-723 (Zurletrectinib)I20DLTIIRP2D8
NTRK75%ORR129PRRP2D77.8%ORR97 PR12IND
CDECDE
ICP-189ICP-B05ICP-033ICP-189
ICP-189SHP2
IaICP-189
40DLTPKICP-189201PR
┃
ICP-B05 (CM369)ICP-B05C-C8CCR8INDIICP-B05
┃
8,697,9275,928,7163,969,6403,969,6401,876,61810,321,1587,397,5314,537,7102,615,6932,201,159
2,676,8311,738,6121,738,6125,563,4393,039,533
625,4041,043,0331,3641,2471,617(143,397)(65,667)–––198,199217,938271,304104,44931,395(438,611)(298,463)(68,208)(3,458)(558)(639,139)(721,584)(402,771)(213,123)(149,726)(181,556)(139,815)(89,371)(63,623)(17,523)(291,167)(1,271)(1,489)(2)(710)(17,045)(2,642)(1,139)(1,916)(3,441)
-––(69,181)(1,814,018)(387,804)
3,396(51,014)(32,374)(159,907)(27,269)
(100)(32)–––(9,711)(604)––(4)–(46,558)–––
(893,727)(66,679)(391,865)(2,150,351)(554,023)
0.600.050.409.322.83
┃
625,4041,043,033198,199217,938(438,611)(298,463)(639,139)(721,584)(181,556)(139,815)(291,167)(1,271)(893,727)(66,679) (473,691)2,630
214.7163.6%
565.9
625.41,043.0417.6
776.0
217.9
198.2(i)57.1(ii)0.078.4
8.5(iii)16.329.9
46.2(iv)135.11.8
136.9
1,161.11,550.5(i)
57.1290.6(ii)304.5115.4419.9
273.02.5(iii)
298.5140.1438.6
┃
66.7
893.7
2.6
473.7
(893,727) (66,679)290,559 (57,135)129,477126,444(473,691)2,630
┃
BTKi
?
566163.6%3001,500CSCOCSCO
┃
TafasitamabCD19Minjuvi
?
ASCTDLBCLTafasitamabFDABDLBCLTafasitamabBLA2022CSCODLBCLTafasitamab
1330ASCODLBCL-MCDDLBCL-MCD75%CRIIIMSII12
Gd+T180QD
92.1IIRMS
BTKiSLEIIa
SLEBTKTICP-332TKY2JH1IICP-488TKY2JH2
┃
2.0
1.0
2.0
ICP-248 (BCL-2)ICP-490 (E3Ligase)ICP-B02 (CD3xCD20)Tafasitamab (ICP-B04) (CD19)
DLBCL
BT
NCEBT
ICP-192ICP-723
ICP-189 (SHP2)ICP-B05 (CCR8)ICP-033 (VEGFR,DDR1)
┃
┃
Tafasitamab
?
163.6%DLBCLCD19Tafasitamab
BLA? 13
PoCMSITP
1L DLBCL-MCD1L CLL/SLL1L MCLMZLWMMCL ICP-192SLEPoCMSPoC12
ITPIIPoCBTKi? TYK2ICP-332ICP-488
CD3xCD20BCL-2E3 LigaseCCR8SHP2?
┃
CMC
?
┃
?
BTKCLL/SLLMCL
625.4565.9
163.6%250
3001,5006,000
DOT
?BTK
?
CSCOCLL/SLLMCLBTKDLBCLpCNSL
┃
NDA
IND Enabling
PH3PHIaPH2*
FiledPHIbPH2**
Market
ICP-022/Orelabrutinib
BTK
r/r WMr/r CLL/SLLr/r MCLr/r MZL
ICP-B02CD3 x CD20
ICP-248BCL-2
ICP-490E3Ligase
1L:CLL/SLL
Tafa+ LEN, r/r DLBCLr/r MCL1L:MCL
ICP-B04/
Tafasitamab
CD19
1L:MCD DLBCL
HKTafa+ LEN + OrelaNHL
CHN,SG
CHN
CCR8ICP-B05Hemato-oncologyNHL/ALLMM/DLBCL
202012252020122520228NDANMPA2022NDANMPA2022
202212202332022720233
NDA
IND Enabling
PH3PHIaPH2*
FiledPHIbPH2**
Market
ICP-B05
pan-FGFRpan-TRKICP-192/GunagratinibICP-723/ZurletrectinibVEGFR, DDR1ICP-033
SHP2ICP-189
CCR8
BTKTYK2 –JH1TYK2 –JH2ICP-022/OrelabrutinibICP-332ICP-488
NTRK
IIPoC
20232
INDFDA
┃
BTBT
MSITPNMOSD
CSU
ICP-332 (TYK2i-JH1)ICP-488 (TYK2i-JH2)
ADPsoriasis
IBD
LN
CD
UC
SLE
T
(BTKi)B
NMOSD:
ITP:
CSU:
SLE:
AD:
IBD:
LN:
CD:
IIaIIb
IIPoCIIPoCII
MS:
III
CNSBSLEIIaSLEBTKIIbMSIIPoCITPNMOSDII
CSU
TTYK2ICP-332ICP-488TADSLEIBDLNCDUC
BICP-332ICP-488T
┃
BBTKTECBBCR
BBTKBTK
MS
MSIIIIRMSOLERMS1:1:1:1
450QD50BID80QDOLE
GdE T1 MRI12GdET1MRI
13612Gd+T150QD71.1% (p=0.0238)50BID80.8%(p=0.0032)80QD92.1%(p=0.0006)
12Gd+T1
Placebo
Orela 50mg QD
| N=33 |
Orela 50mg BID
Orela 80mg QD
| N=34 |
71.1%,
P=0.0238
80.8%,
P=0.0032
92.1%,
P=0.0006
1CI QD=BID=pPearson
┃
RMSII
InnoCare80mg QD92.1%Cumulative Gd+lesionsatWk12Placebo-controlled(N = 136), 24Wk + extSano?60mg QD85%(2)Dose-response for Gd+
lesions at Wk12Placebo-controlled for 4Wk, with12Wk cross-over (N=130), 16Wk + ext
MerckKGaA75mg qd(56% at75mg bid)70%
(3)Cumulative Gd+ lesions at Wk12,
16, 20, and 24Placebo-controlled + open label DMF (N =
267),24Wk + ext
BTK
Roche600mg q6mo89%(4)Cumulative Gd+ lesions at
Wk12, 16, 20, and 24Placebo-controlled + Inf-b1a referencearm (N=218), 24Wk + ext
Novartis60mg q12w65%
(5)(6)
91%
(7)
Cumulative Gd+ lesions at
Wk 12Placebo-controlled (N=231), 24Wk +
ext
Novartis2mg qd72%(8)Dose-response for CUAL at
3 moPlacebo-controlled, adaptive, doseranging
(N = 297), 6m + ext
Biogen240mg tid69%
(9)Cumulative Gd+ lesions at Wk12,
16, 20, and 24Placebo-controlled(N = 257),24Wk + ext
Novartis5mg qd61%(10)88% atmo. 6Cumulative Gd+ lesions
monthly for 6 monthsPlacebo-controlled (N = 281), 6m + ext
Sano?14mg qd61%
(11)
# of CUAL per MRI scanPlacebo-controlled (N = 179), 36Wk + ext
T1BTKTolebrutinibBTK
CD20CD20S1PRS1PR
(1)
1 www.clinicaltrials.gov; (2)Sanofi’s R&D held on April 23, 2020;(3) MontalbanX, et al. N Engl J Med 2019; 380:2406-2417;(4) KapposL, et al. Lancet 2011;378:1779-87 (5) Bar-Or A. et al, Neurology 2018;90:e1805-e1814; (6)Endpointwith full data (0-12 Wks) (7) Post hoc data (4-12 wks);(8) Selmaj K, et al Lancet Neurol 2013;12:756-767;(9) KapposL, et al. Lancet 2008;372(9648):1463-72;(10) Kappos L, et al. N Engl J Med 2006; 355:1124-40;(11) O’Connor P, et al.Neurology 2006;66(6)
MSMS
┃
CNSPKBBBMS
PKBTKevobrutinibtolebrutinibevobrutinibtolebrutinibCNS
plasmacyte
BB
B
B
T
T
BTK+
(CNS)
AQP4
T
MoG
TT
BTK(mg)
CSF Conc. ~2h
(ng/mL)
Orelabrutinib150 QD
31.3
InnoCareEvobrutinibMerck KGaA75 BID
3.21
Sano?120 QD
(ng/mL)
13.4
1.87
Tolebrutinib
1 doi: 10.1016/j.msard.2021.1030002 Multiple Sclerosis and Related Disorders 51 (2021) 103001 Topic: Advances in therapy in MS; doi: 10.1016/
j.msard.2021.103001
┃
EAEMSMOGEAEEAE
EAEMS
MSDMTFDABiolato M, Bianco A,Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-RemittingMultiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs . 2021 Aug;35(8):861-880
26MS2624
HBVDMTBiolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M,Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: ANarrative Review. CNS Drugs. 2021 Aug;35(8):861-880ALT
┃
ALTβ136
136912C
62C
BC
AALTFDA
IIMSIBICFFDAiDMCiHACFDAFDA
MSMS
8.125
┃
MS
BMSIIMSOLE
MSBTKSLEBTKBCRBSLE
SLEIIEULAR
SLE1:1:1:1125080100II
508010012SRI-435.7%50.0%61.5%64.3%
GC3C4
┃
IIaSLE
IIbSLESLESLE
1:1:1255048
SRI-4SRI-6C3C4dsNDA
35.7%
50.0%
61.5%
64.3%
14.3%
25.8%
28.6%
(n=55)
0%10%20%30%40%50%60%70%80%90%
| 100% |
(N=14)
(N=14)
(N=13)
(N=14)
SLEBTKevobrutinibfenebrutinibRingheim, G. E., Wampole, M., & Oberoi, K. (2021)Frontiers in Immunology, 12, 662223SLEBTK
SLEITPITPITP
TBTKBITPB
BTKITPITP
┃
ITPIIIIITPIII
×
/L2722GCIVIG5075.0%8636.4%331240%15650IIITP
NMOSDNMOSD
45-650.445/100,0004.71:1NMOSDB4AQP4 IgG80%
AQP4 IgGBTKBBBTKBTK
BTKNMOSD
IITIIIIT
┃
T–TYK2ICP-332ICP-332TYK2TYK2JAKIL-12/IL-23IFN
T17TH17TH1BADICP-332TYK2400JAK2JAK
TYK2ICP-332
IBDPharma Intelligence12
0.96-22.6%1.2-17.1%100
ICP-332
CDEICP-332I
IIPK/PDJAK-2AEADII
I14ICP-332532040160QDPKPD8ICP-3326280ICP-322ICP-3325320PKCmaxAUClast
320160QDICP-332
┃
ICP-488ICP-488TYK2JH2JH2TYK2JH2
TYK2ICP-488TYK2TYK2 JH2IL-23IL-12IIFNICP-488SLELNIBDICP-332ICP-488TYK2I136SADMAD
ICP-488
ICP-248ICP-490ICP-B02TafasitamabNHLMM
DLBCLNMNHL(i)(ii)FDAEMACD19TafasitamabDLBCL(iii)CD20xCD3BCL-2E3 Ligase(iv)
DLBCLTafasitamabBCL-2 E3 LigaseDLBCL1L DLBCLMCDTafasitamabDLBCL
ICP-248
ICP-B02
ICP-248Orelabrutinib
TafasitamabICP-490
ICP-B05/CM369ICP-490
OthersCMLALLAMLPTCL/CTCLDLBCLCNSLFLWMMZLMCLCLL/SLLOthersMM
┃
NHL
CLL/SLLMCLCDE5
MCL
AE31L CLL/SLL
IIICLL/SLL
IRCPFS
CLL/SLLIICLL/SLL15080CLL/SLL47
56.2%ORR93.8%CR30%
1.84DORPFS48DORPFS56.2%52.7%CLL/SLLBTKCR
AE
CLL/SLLGazyvaFCRBTKi
7.1611.073PR/PR-LSDORR75%DCR100%BTKiCLL/CLL
1L MCL
IIIR-CHOPR-CHOPIRC
iwNHLPFS
┃
MCLIIMCL
DORPFSOS10639.43
10683%
87.8%CT36.8%
MCLTRAE
MCLIIFDABTDMCL
WMWMBMIgMBTKWMMYD88L265P
BTKBTK
WMIRCMRRMRRORRDOMRPFSOS
24.90MRR80.9%ORR91.5%12DOMR
84.9%12PFS81.2%PFSAE
(Lancet eClinicalmedicine)
MZL
II150MZL
11190MZL90MZL53PR43CR10IRCORR58.9%95% CI48.069.2DOR
┃
34.395% CINANAPFSOSIRC12PFSOS82.8%91%ibrutinibMZL
ORRCRPFSOSCDECDEMZLBTKNHLDLBCL
1L DLBCL-MCDDLBCLNHL100MCD1L DLBCLIII
R-CHOPR-CHOPMCDDLBCLIRCPFS4540%DLBCL
R-CHOP+XMCDBNF-KBBTK
TITKCD20NKADCC
R-CHOPMCDDLBCLASCOR-CHOPMCD DLBCL
14MCD DLBCL1508R-CHOPR-EPOCH6RICER-CHOPR2CRR75%66.67%
MCDDLBCL
MCDDLBCLTafasitamab (CD19)ICP-B02 (CD3xCD20)ICP-490E3
DLBCL
┃
pCNSLpCNSL
pCNSLND pCNSLCNSLpCNSLORRCR88.9%100%53.9%
61.8%ND pCNSL
PFSmPFS6PFS63.6%100%60%CNSLORR60%86.7%mPFS9.83mPFSBCRMYD88MOABBB15021.6BBB
58.6%
pCNSL
BTKCD20
BTKBBCRCD20CDCADCC/ADCPBTK2IL-2-ITKNKADCC
(Mol Ther Oncolytics 21: 158-1702021BTKBTKB
ADCCMol Ther Oncolytics 21:158-1702021Gazyva
ADCCADCPCD20CD19Tafasitamab
┃
ADCP
| BTKi + Gazyva(Obinutuzumab) |
(Reporter assays: TMD8 as target cell)
Jurkat-NFAT-Luc2-CD16A-V158
GazyvaGazyva + Ibrutinib (5?M)Gazyva+ Orelabrutinib (5?M)
Jurkat-NFAT-Luc2-CD32a-R167GazyvaGazyva + Ibrutinib (5?M)Gazyva+ Orelabrutinib (5?M)
Log [Test Articles] (ng/mL)Log [Test Articles] (ng/mL)
200015001000
15001000
Luminescence (RLU)Luminescence (RLU)
-205-140312
4312
CD20Gazyva(obinutuzumab)ADCCADCP
BTKCD20/CD19B
CD20GazyvaBTafasitamabNHLIIICP-B04 (Tafasitamab)
CSCOTafasitamabCSCOASCTDLBCL
DLBCLCHOP
Tafasitamab
TafasitamabTafasitamabTafasitamabNMPA
2CR
Tafasitamab18TafasitamabDLBCL
┃
TafasitamabDLBCLII
IITafasitamabDLBCLORRIRCDCRDoRPFSTTPTTROS24
TafasitamabBDLBCL
NHL40%Frost & SullivanDLBCL59
119NHL/DLBCLTafasitamab
IncyteTafasitamabFcCD19TafasitamabFDA
DLBCLDLBCLASCTIIL-MIND57.5% ORR(40% CR)33.5mOS43.9mDoRTafasitamab
CD19B-NHLB-NHLRE-MIND2R2Tafasitamab
Incyte35Incyte
82.5
TafasitamabIncyteBTK
TafasitamabTafasitamabB
TafasitamabADCCADCPBCD19
IncyteTafasitamab
┃
ICP-B02 (CM355)ICP-B02CD20xCD3
TDCCICP-B0250%
ICP-B0250%
I/IIICP-B02NHLPKIICP-B02DLT
53+3DLTICP-B02BICP-B02SCIND
CDEMMICP-490
ICP-490CRBN E3TPD
CRL4CRBN-E3ICP-490IKZF1IkarosIKZF3AiolosICP-490CRBN E3
AiolosIkarosICP-490MMBDLBCLICP-490
CRNBICP-490ADCCCD38daratumumabICP-490DLBCLICP-490
MMIMiDMMNHLINDCDEI
┃
ICP-248ICP-248B2BCL-2BCL-2BCL-2
BCL-2
ICP-248ICP-248BCL-2ICP-248ALLAMLFLCLLDLBCLBCL-210%20ICP-248ICP-248INDCDEIIICP-248BCLL/SLLMCLICP-248ICP-248
CLL/SLL
ICP-192ICP-723
ICP-189ICP-B05ICP-033
┃
ICP-192 (Gunagratinib)
ORR52.9%DCR 94.1%ICP-723 (Zurletrectinib)
NTRK8ORR75%
ICP-189
SHP-2
ICP-B05
CCR8
EGFRiRTKiKRASiVEGFi
ICICDK4/6i
RAFiMEKiPD-1/PD-L 1
FGFRICP-192TRKICP-723
SHP2CCR8ICP-189ICP-B05ICP-033ICP-192 (Gunagratinib)GunagratinibFGFRFGFR
7.1%
FGFR
┃
GunagratinibFGFRFGFR
GunagratinibFGFR
GunagratinibCCAIIaICP-19218CCA175.57ORR52.9%179DCR94.1%1716mPFS6.9395% CI5.42TRAE
FGFRGunagratinibCCAFGR2(52.9%)GunagratinibI/II
IIIIORR
44.4%94DCR88.9%98ICP-723 (Zurletrectinib)ICP-723TRKTRK
TRKNTRKTRKTRKICP-723
TRKA/B/CTRKAG595RG667CICP-723TRKICP-723ROS1ROS1
TRKTRKATRKBTRKCNTRK1NTRK2NTRK3TRKNTRKNTRKNTRKC-Ros1 (ROS1)
NSCLCROS1NSCLC
┃
I/IIICP-723NTRK/ROS1PKASCO
I/IIIIIIIINTRKROS1TRKROS1I24DLTIIRP2D8NTRK75%ORR129 PR877.8% ORR97 PR6ROS1ORR50%4
PRDLT12INDCDECDEEoP2ICP-189
ICP-189SHP2ICP-189SHP2RAS-MAPK
PD-1SHP2ICP-189ICP-189EGFRKRASMEKPD-1
IaICP-189
40DLT3TRAESAEICP-189201PRICP-189PKICP-189Ib
ICP-189EGFRPD-1ICP-189INDFDA
┃
ICP-B05 (CM369)ICP-B05C-C8CCR8
CCR8TMETTregsCM369TregsCCR8ADCCTregsTMECM369TICP-B05INDCDE
IICP-B05ICP-B05ICP-033ICP-0331DDR1VEGFRICP-033ICP-033
ICP-033I
PROTACXDC
50,000GMP
NMPABTK
┃
30,000
CMC70,381
29.19
┃
MSBTK
%%
566,75590.6214,66620.6
58,6499.452,4045.0––775,96374.4
625,404100.01,043,033100.0
1,043.0
625.4
352.1164.0%566.8
776.0
%%
471,17097.8191,00819.5
10,8372.210,3951.1––775,96379.4
482,007100.0977,366100.0
977.493.7%
482.077.1%
┃
217.9
198.2(i)57.1(ii)0.078.4
8.5(iii)16.329.9
46.2(iv)135.11.8
136.9
721.6
639.1
%%
2,4900.4273,02637.8 196,82630.8167,58923.2
223,09534.9136,92319.0
58,1649.139,4285.543,0836.721,8373.0115,48118.182,78111.5
639,139100.0721,584100.0
(i) 273.0270.52.5(ii) 167.629.2196.8(iii) 136.986.2223.1(iv) 39.418.858.2(v) 21.821.343.1(vi) 82.832.7
115.5
┃
139.8
181.6(i)47.0
78.0(ii)3.6
11.3(iii)1.46.9(iv)
9.215.8
%%
78,00843.046,96433.634,35718.943,01730.835,15919.435,56325.411,2976.23,6372.66,8953.81,3921.015,8408.79,2426.6
181,556100.0139,815100.0
298.5
438.6(i)
126.5219.4(ii)100.7
143.1
%%
219,42250.0126,46242.4143,10532.6100,71233.736,9568.543,99914.739,1288.927,2909.2
438,611100.0298,463100.0
┃
57.1
290.6
51.0
3.4
9.7
0.6
2.6
17.0
46.6
┃
127,82545,27395,344116,14565,3229,918313,290317,0598,697,9275,928,716
9,299,7086,417,111
118,59784,6024,2426,831727,552204,8867,75712,64720,11220,3361,197,168–
2,075,428329,302
7,224,2806,087,809
7,224.38,697.9127.8
95.3313.3
727.6118.61,197.2
┃
127,82245,273
3–
127,82545,273
116.1
95.3
16.316.3
33,55737,53244,98741,363–16,34012,14717,3624,6533,548
95,344116,145
313.3
317.1304.7
┃
9.9
65.3
111,18684,4597,3351216617
118,59784,602
204.9
727.6(i)
47.0104.1(ii)
41.457.0(iii)
33.1
7.6(iv)23.0
51.4(v)
459.5
104,05046,95657,01441,40632,58037,3607,62833,07051,39123,024–20,000459,517–15,3723,070
727,552204,886
┃
20,11220,336459,517–1,197,168–
35,43947,442287,76137,693
–1,200,564
1,999,9971,306,035
1,306.02,000.0
136.3
286.0
430.1
653.2
136.0
284.1
34.2
41.3SAP
21.4
11.7
┃
51.0
28.0
4.519.5
1,197.2
204.9727.6
84.6118.6
5,928.78,697.9
8.95250,324,000
0.0000023,8832,240.4
H.10
37,548,00015%322.59
210,508,000
14.45
┃
264,648,2170.000002
11.03
2,778.82
9,011.26,550.5
(i)8.5(ii)6.6
100%18.8%17%
┃
1,197.2
287.8459.5
163.4
262829
┃
41844.5%15016%26127.8%11011.7%939100%
┃
Ph.D.60
MerckCo
PPD?
BioDuro LLC(Sino-American Pharmaceutical Association)1750
NatureBloodProceedings of the National Academy of SciencesJournal of BiologicalChemistryTransgenic mice expressing APC resistanceFactor Vcloning and expression of dog gonadotropin releasing hormone receptorDNA encodingmonkey gonadotropin releasing hormone receptor
(PurdueUniversity)?(The HowardHughes Medical Institute)Ph.D.54
Shenzhou Tianchen Technology Inc
?(Johns Hopkins University)
┃
Ph.D.55
(Princeton University)
? (The National Science Fund for Distinguished Young Scholars)
(The Irving Sigal Young Investigator Award)? (The Raymond & Beverly
Sackler International Prize)??? (The Gregori Aminoff Prize, Royal Swedish Academy
of Sciences)?? (The National Innovation Award)?
? Structures of the Human Spliceosomes Before and After Release of the Ligated Exon? Structures of the Catalytically Activated Yeast Spliceosome Reveal the Mechanism of Branching? Recognition of the Amyloid Precursor Protein by Human -Secretase
┃
? Structural Basis of Notch Recognition by Human -Secretase? Structure of a Human Catalytic Step I Spliceosome? Structures of the Fully Assembled Saccharomyces Cerevisiae Spliceosome Before Activation? Structure of the Human PKD1/PKD2 Complex? Structures of the Human Pre-Catalytic Spliceosome and its Precursor Spliceosome
(Johns Hopkins University)
Blackstone (Shanghai) Equity Investment ManagementCompany LimitedVivo Capital LLC01875
Sinovac Biotech Co , Ltd.SVAGenetron Holdings LimitedGTH
2291
3810
Oriza Cowin
688578
0992602171
┃
Ph.D.55
Genentech IncAnalytical BioSciences Limited
1875
Arther Andersen
CICPA
┃
Ph.D.77
?????
1349Zai Lab LimitedZLAB96881801
600557
┃
Ph.D.60
3020
Merck & Co.
Bristol-Myers SquibbGlaxoSmithKline
Hengrui Therapeutics Inc. (HTI) Princeton
(USMLE)(FCP)
Bruker Daltonics China
┃
Ph.D.56
IND2317Albert Einstein College of Medicine
Pfizer Inc
┃
1291
122128
┃
430.1
653.2
8.08
┃
2,415.671,260.2
52.2%
50%
1,207,835853,114441,116411,998
40%*966,268812,054115,853696,201
10%
241,56763,66616,35047,316
2,415,6701,728,834573,3191,155,515
*
(i)(ii)
┃
Gaoling Fund L.P.YHG Investment L.P.Vivo Opportunity Fund, L.P.
210,508,000
16.33%14.04%14.45
421.023,041.44210,508,000
14.45
15.723,041.843,041.44
3,041,4401,704,4981,336,942
2,919.07
140.252,778.82
545.7
┃
1,494,220.6–1,494,220.6116,146.6–116,146.6273,851.4–273,851.4
60,952.3–60,952.3833,644.7–833,644.7
2,778,815.6–2,778,815.6
┃
183171712-1716
6225
┃
13.9127
?????
┃
????????? EHS
EHS
┃
1.0
2.0
BT
Multiple Sclerosis International FederationMSIF280MSFrost & SullivanMS230
317BTKBMSBTKMSBBBMSBTKIIMSMSBTK
BSLEIIaSLEBTK
ITPNMOSDIITICP-332ICP-488TADSLELNIBDBICP-332ICP-488T
┃
ICP-248ICP-490ICP-B02TafasitamabMMNHL
?
BMZLWMCLL/SLLMCLMCDDLBCL
MCLNHL
ICP-192ICP-723ICP-189ICP-B05ICP-033
IND
ICP-B02ICP-B05Tafasitamab
┃
┃
114(a)
6167
13.51B(1)
┃
3.13
XV(a)XV78(b)352(c)
(1)103,222,916
(2)
5.85%
119,839,593
(3)
6.79%
119,839,893
(4)
6.79%
8,311,1110.55%
(1) 1,764,321,452
(2) (i)Sunland BioMed Ltd82,326,827(ii)
20,896,089
(3) (i)Sunny View Holdings Limited99,360,375(ii)
20,479,218
(4) XV
┃
XVXV
XV23XV336
(1)
TMF (Cayman) Ltd.89,014,653
(2)
5.04%
GIC Private Limited97,614,645
(3)
5.53%
Vivo Capital VIII, LLC123,028,118
(4)
6.97%
Hebert Pang Kee Chan163,444,332
(5)
9.30%
HHLR Advisors, Ltd.208,671,222
(6)
11.83%
(1) 1,764,321,452
(2) Golden Autumn Group LimitedStrausberg Group Limited47,900,27841,114,375Golden
Autumn Group LimitedStrausberg Group LimitedLakeview TrustSummit TrustTMF(Cayman) LtdLakeview TrustSummit TrustTMF (Cayman) Ltd47,900,27841,114,375890,014,653
(3) Highbury Investment Pte Ltd42,559,355Highbury Investment Pte Ltd
Loyal Valley Capital Advantage Fund II LP45,487,484LVC Lion Fund LPLoyal Capital Advantage Fund II LPLVC Lion Fund LP9,567,806
Highbury Investment Pte LtdGIC (Ventures) PrivateLimitedGIC Special Investments Private LimitedGIC Special Investments Private LimitedGIC PrivateLimitedGIC (Ventures) Private LimitedGIC Special Investments PrivateLimitedGIC Private LimitedHighbury Investment Pte Ltd97,614,645
┃
(4) Vivo Capital LLC(i) Vivo Opportunity Co-Invest, L.P.(ii) Vivo Capital Fund IX, L.P.(iii) Vivo Opportunity Fund, L.P.
(iv) Vivo Capital Surplus Fund VIII, L.P.(v) Vivo Capital Fund VIII, L.P.Vivo2,699,2861,891,62724,673,08711,376,77982,387,339VivoCapital LLCVivoVivo123,028,118
(5) Hebert Pang Kee Chan163,444,332(i)Success Growth Limited55,500,000
(ii)King Bridge Investments Limited106,807,145(iii)1,137,187Success Growth Limited55,500,000Success Growth LimitedKing BridgeInvestments LimitedHebert Pang Kee ChanHebert Pang Kee ChanGoldenSage Investments Limited
(6) HHLR Advisors, Ltd.Hillhouse Capital Advisors, Ltd.HHLR Fund, L.P.Gaoling Fund, L.P.YHG
Investment, L.P.HillhouseHHLR Fund L.P.200,475,300HHLR Advisors, Ltd.HillhouseHillhouse
208,671,222
XV23XV336
8.10
┃
14A.4914A.71
┃
939721
1.
(i)(ii)(iii)
┃
2.
3.
┃
274,586,514183,888,050
22,200,00068,498,464
15.56%10.42%
1.26%3.88%222,308,15784,894,476Golden Autumn Group LimitedStrausberg Group Limited
Golden Autumn Group LimitedStrausberg GroupLimitedLakeview TrustSummit TrustTMF (Cayman)Ltd.
(10%)
0.0000020.178
52,278,3572.96%
17.12
┃
2022
(3)
20221231
(1)
2022
1231
(4)
3,333,33303,333,333000020151.22533,333,33303,333,333000011,900,0000000011,900,000201811,900,0000000011,900,000
┃
2022
(3)
20221231
(1)
2022
1231
(4)
4,655,7120441,205990,000003,224,50720151.22533,000,0000525,0000002,475,00020161.294114,682,0002,700,0003,414,0001,734,7500012,233,250201803/16/20221.0912022/3/16-
2026/3/15
0.1789.931.1640
04/28/20221.1806
(2)
0.17810.66
09/16/20221.22342022/9/16-
2026/9/15
0.17811
22,337,7122,700,0004,380,2052,724,7500017,932,75737,571,0452,700,0007,713,5382,724,7500029,832,757
(1) 332.4(2)(3)
(4) 17.07(3)
┃
1717
10%10%128,916,5247.3%
128,916,524128,916,524
┃
1717
17.12
12.8%34.6%
13.1%41.6%
5%
┃
0.5
C.2.1(i)(ii)
(iii)
┃
13.1713.22
┃
C.2.1
┃
(www.innocarepharam.com)
(www.innocarepharam.com)
(www.innocarepharam.com)
┃
┃
(1)
(2)13/13–2/22/21/113/13–––1/113/13–––0/12/2––––13/13–––1/113/13–––0/111/11–––0/113/135/52/22/20/113/135/52/2–0/113/135/5–2/20/1
(1)(2)
┃
3.10(1)(2)3.10A
3.13
C.2.7
┃
C.1.4
??????????
1.
┃
(i)(ii)
(iii)
114. (a)
┃
3.10(2)3.21
(i)(ii)
(iii)
┃
17.07A
4,500,0015,000,0001–9,000,0019,500,000–110,500,00111,000,000–115,500,00116,000,0001–17,000,00117,500,000–128,000,00128,500,0001–30,500,00131,000,0001–36,500,00137,000,000–1
┃
16,10812,8737,4244,94134325370,24772,670–33
94,12290,770
(a)(b)
(c)
┃
┃
(i)(ii)
A.2.1
3.2915
┃
(i)(ii)(iii)(iv)
(v)
┃
(i)(ii)(iii)(iv)(v)(vi)(vii)
(viii)
(i)(ii)(iii)(iv)(v)(vi)
┃
(i)(ii)
┃
(www.innocarepharam.com)
(www.innocarepharam.com)
┃
5,6832,000 500
8,183
3877
┃
(6)(3)
(4)(3)(2)<=50(2)
50-69(3)
=>70(1)0-1(2)
2-3(2)
4-5(3)
>=6(2)
(5)
1-2(1)
3-4(3)
>=5(0)
(i)(ii)(iii)
(iv)
93950143843.4%46.6%
┃
212121
┃
www.innocarepharma.com
88 ir@innocarepharma.com
2630
┃
(i)(ii)
115121
┃
┃
Ernst & Young27/F, One Taikoo Place979 King’s Road
122128
┃
639,139,000
2.4
(1)(2)(3)(4)
(5)
(6)
┃
625,404,000
2.4
(1)(2)
(3)(4)
(5)(6)(7)
┃
(1)(2)
1,197,168,000
2.4
32839
(1)
(2)
(3)
┃
┃
?
???
┃
??
Shun Lung Wai, Ricky
┃
5625,4041,043,033
(143,397)(65,667)
482,007977,3665198,199217,938
(438,611)(298,463)(639,139)(721,584)(181,556)(139,815)(291,167)(1,271)283,396(51,014)
(100)(32)
(9,711)(604)7(17,045)(2,642)
(893,727)(20,121)10–(46,558)
(893,727)(66,679)
(886,593)(64,545) (7,134)(2,134)
(893,727)(66,679)
120.600.05
┃
(893,727)(66,679)
429,445(89,453)
429,445(89,453)
(464,282)(156,132)
(457,148)(153,998) (7,134)(2,134)
(464,282)(156,132)
┃
13653,163430,08114284,103135,999153,1253,1251641,30534,1661711,71221,42322–304,6751828,04250,951
1,021,450980,420
1965,3229,91820127,82545,2732195,344116,14522313,290317,059238,697,9275,928,716
9,299,7086,417,111
24118,59784,602254,2426,83126727,552204,886277,75712,6471420,11220,336281,197,168–
2,075,428329,302
7,224,2806,087,809
8,245,7307,068,229
28–1,200,5641435,43947,44229287,76137,69327278,203123,611
601,4031,409,310
7,644,3275,658,919
312319327,597,0785,604,540
7,597,1015,604,559
47,22654,360
7,644,3275,658,919
┃
313132(a)3332(b)
199,371,726(19,292)260,235(6,036)(465,758)(3,536,335)5,604,55954,3605,658,919–––––(886,593)(886,593)(7,134)(893,727)
–––––429,445–429,445–429,445
–––––429,445(886,593)(457,148)(7,134)(464,282)
A42,919,066–––––2,919,070–2,919,070
–(149,902)–––––(149,902)–(149,902)33–––129,477–––129,477–129,477
–68,629–(64,345)–––4,284–4,284
–(453,239)–––––(453,239)–(453,239)
2311,756,280*(19,292)*325,367*(6,036)*(36,313)*(4,422,928)*7,597,10147,2267,644,327
┃
313132(a)3332(b)166,743,236(19,292)234,183(6,036)(376,305)(3,471,790)3,104,01256,4943,160,506––––––(64,545)(64,545)(2,134)(66,679)–––––(89,453)–(89,453)–(89,453)–––––(89,453)(64,545)(153,998)(2,134)(156,132)3132,526,672–––––2,526,675–2,526,67533–––126,444–––126,444–126,444
–101,818–(100,392)–––1,426–1,426199,371,726*(19,292)*260,235*(6,036)*(465,758)*(3,536,335)*5,604,55954,3605,658,919* 7,597,078,0005,604,540,000
┃
(893,727)(20,121) 10032 717,0452,642 290,559(44,138) 5(136,914)(135,135) 5(8,486)(70) 179,711604 28(3,396)51,014 5(6,557)(6,733) (73)– 635,35310,438 621,53317,752 11,5175,521 –2 6129,477126,444
(533,858)8,252
(52,116)(8,040)(82,653)(45,153)
(932)(1,349)
33,99579,08235,35476,565(8,748)17,191
(608,958)126,548
43,40440,510
(565,554)167,058
98,37279,568
–(715,000)315,0002,611,467
(227,235)(169,770)(11,724)(1,441)74,971–(20,000)(868)
–19(131,368)–(1,824,370)(3,533,940)
(1,726,354)(1,729,965)
┃
4,160784A2,919,070–
(128,686)(15,207)
–2,526,675325,00050,000(3,263)(2,529)(21,775)(14,916)
3,094,5062,544,807
802,598981,900
3,237,4842,300,881
139,902(45,297)
234,179,9843,237,484
238,697,9275,928,71623(4,515,379)(2,691,009)
(2,564)(223)
234,179,9843,237,484
┃
1.
OgierGlobal (Cayman)Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009 Cayman Islands
1100%–1–100%InnoCare Pharma Inc.10,000,000–100%InnoCare Pharma Australia Pty Ltd.10–100%
(a)
80,000,000–100%
10,000,000–100%49,225,100–91.08%
4,000,000–100%
1,000,000,000–93%(a)30,000,000–100%(a)
┃
2.1
(a)(b)(c)
┃
2.1
(i)(ii)(iii)(i)(ii)(iii)
2.2
1641
(a) 3
3721
┃
2.2
(b) 16
(c) 3737
(d)
91641? 9
┃
2.3
1, 5
2, 4
5 174
6 17
┃
2.3
102810
┃
2.3
1212
7,852,0007,877,000
┃
2.4
20%
┃
2.4
┃
2.4
┃
2.4
–––
┃
2.4
(a)
(i)(ii)(iii)
(b)
(i)(ii)(iii)(iv)(v)(vi) (a)(vii) (a)(i)(viii)
┃
2.4
5%10%33
/
%10%33
/
%
/
%
┃
2.4
┃
2.4
(a)
(b)
┃
2.4
(c)
SPPISPPI
┃
2.4
┃
2.4
??
(a)(b)
┃
2.4
1212
–12––
┃
2.4
┃
2.4
┃
2.4
??
┃
2.4
??
┃
2.4
┃
2.4
(a)
(a)(b)
???
┃
2.4
(a)
15.85
┃
2.4
(a)
(b)
┃
2.4
(a)(b)(c)
┃
2.4
┃
2.4
┃
2.4
┃
3.
(i)
┃
3.
(ii)
(iii)
┃
3.
3,125,0003,125,00015
2238
┃
3.
1,511,700,0001,177,329,00010
┃
4.
(a)
568,035216,066
57,369826,967
625,4041,043,033
(b)
1,020,695674,729
7551,016
1,021,450675,745
10%
A*826,967B224,090*C101,386*D81,916*
407,392826,967
* 10%
┃
5.
625,4041,043,033
(a)
–775,963 566,755214,666 57,36951,003 1,2801,401
625,4041,043,033
568,035216,066 57,369826,967
625,4041,043,033
568,035992,030 57,36951,003
625,4041,043,033
Biogen Inc.MSBTK
┃
5.
(a)
7,797–
(b)
3090
17,7837,797–17,78317,78325,580
┃
5.
(b)
46,15916,257136,914135,1358,48670832,608191,642154,0706,5576,733–57,135198,199217,938
┃
6.
35,35310,43821,53317,752
164,5854,292
5,6833,080580,975682,15628(3,396)51,014
6,5576,733290,559(57,135)378,284232,263
66,46038,974
6,4116,354129,477126,444580,632404,035
7.
14(b)2,7042,560
8,06382
6,278–17,0452,642
┃
8.
383(1)(a)(b)(c)(f)2
720753 6,4094,475 3,8882,304 9690 16,14226,314
27,25533,936
(a)
––
360360
360360
720720
┃
8.
(a)
–––––6–6
–5––––
–5
┃
8.
(b)
–4,2473,240–16,142 **23,629
–2,16264896–2,906
–6,4093,8889616,14226,535 –––––– *–––––– –––––– –––––– *––––––
––––––
–6,4093,8889616,14226,535
┃
8.
(b)
333,1431,680–24,557 **29,413 –1,326624901,7523,792
334,4692,3049026,30933,205 –––––– –––––– –––––– *–––––– *––––––
–––––
334,4692,3049026,30933,205
***
┃
9.
11,8619,7304,1843,26134325354,10548,11370,49361,357
4,500,0015,000,0001–9,000,0019,500,000–110,500,00111,000,000–115,500,00116,000,0001–17,000,00117,500,000–128,000,00128,500,0001–30,500,00131,000,0001–36,500,00137,000,000–1
┃
10.
16.5%16.5%
2,000,0002,000,0008.25%8.25%
16.5%16. 5%
25%15%
15%15%25%
50,000,00025%26%50,000,00030%
30%
┃
10.
21%21%
–52,593–(6,035)–46,558
(893,727)(20,121)25%(223,432)(5,030)
97,15222,37065,183(23,565)(62,491)(56,802)
–(82,003)103,983134,18418,1484,7201,45791–52,593–46,558
1,511,700,000
┃
11.
12.
(886,593)(64,545)
1,479,5651,366,261
┃
13.
81,041119,5697,9966,675230,724446,005–(11,917)(3,037)(970)–(15,924)81,041107,6524,9595,705230,724430,081
81,041107,6524,9595,705230,724430,081–43,7171,6301,908229,509276,764(7,766)(23,281)(2,575)(2,918)–(36,540)143,36774,89930926,854(262,583)(17,154)–84––12
216,642202,9954,32731,549197,650653,163224,408238,1939,93935,437197,650705,627(7,766)(35,198)(5,612)(3,888)–(52,464)216,642202,9954,32731,549197,650653,163
┃
13.
–10,3393,5671,078296,929311,913–(3,725)(1,736)(54)–(5,515)–6,6141,8311,024296,929306,398
–6,6141,8311,024296,929306,398–7,9002,3295,597118,280134,106–(21)–––(21)–(8,193)(1,301)(916)–(10,410)81,041101,3452,099–(184,485)–
–71––8
81,041107,6524,9595,705230,724430,08181,041119,5697,9966,675230,724446,005
–(11,917)(3,037)(970)–(15,924)81,041107,6524,9595,705230,724430,081
(a)
(b)
┃
14.
(a)
21,91074,82396,73358,709–58,709(17,876)(1,543)(19,419)
(24)–(24)
62,71973,280135,999
9,542163,368172,910(20,065)(4,810)(24,875)
69–6952,265231,838284,103
160,101,000
(a)
6,6401,650
(b) 3,350
┃
14.
(b)
67,77823,9989,54258,6942,7042,560
(73)–
(24,478)(17,445)78(29)55,55167,77820,11220,33635,43947,442
(c)
2,7042,56024,87519,4191,943810
(73)–
29,44922,789
34(c)
┃
15.
3,1253,125
60.7%-90%21.5%~90%
0%0%
14.48%14.1%
┃
15.
16.
36,5802,43139,011(3,658)(1,187)(4,845)32,9221,24434,16632,9221,24434,166–11,72411,724(3,658)(927)(4,585)29,26412,04141,305
36,58013,09649,676(7,316)(1,055)(8,371)29,26412,04141,305
┃
16.
36,5801,28037,860–(843)(843)36,58043737,01736,58043737,017–1,4411,441(3,658)(634)(4,292) 32,9221,24434,166
36,5802,43139,011(3,658)(1,187)(4,845)32,9221,24434,166
17.
11,71221,423
2,000,00050%50%50%2,000,00050%50%50%
┃
17.
9,7116049,71160411,71221,42318.
–32,00014,9479,5668,2736,1474,8223,23828,04250,95119.
25,753794
–1,85316,013–23,5567,27165,3229,918
┃
20.
127,95745,304
(132)(31)
127,82545,273
127,82245,273
3–127,82545,273
31–10032
1––(1)13231
┃
20.
127,9570.10%132
45,3040.07%3121.
44,98741,36333,55737,53212,14717,362–16,3404,6533,54895,344116,145
┃
22.
313,290317,059 –304,675
313,290621,734
23.
8,697,9275,928,716(4,515,379)(2,691,009) (2,564)(223)
4,179,9843,237,484
3,947,9183,106,954 215,970103,064 16,09627,466
4,179,9843,237,484
┃
24.
111,18684,4597,335121
6617
118,59784,602
25.
4,2426,831
13,541,0004,242,00018,749,000
6,831,000
┃
26.
104,05046,95657,01441,40632,58037,3607,62833,07051,39123,024459,517–
–20,00015,3723,070
727,552204,886
27.
7,75712,647278,203123,611
285,960136,258
136,258106,646197,06245,868(46,051)(16,256)(1,309)–
285,960136,258
┃
28.
–1,200,5641,197,168–
1,149,550
51,0141,200,564(3,396)1,197,168
9306.5%
29.
37,693–250,62737,693
(559)–
287,76137,693
50,000,000325,000,0000.35%
┃
30.
5,4326,036
(604)(604)
4,8285,432
5,432–
(604)5,432
4,8285,432
––––
┃
31.
50,000500,000,000
0.000125,000,000,000
0.000002
1,764,321,4521,499,673,235 0.0000022319
1,168,170166,743,236a)210,50832,526,672
31,171–101,818
1,409,849199,371,726Ab)264,64842,919,066
––(149,902)––(453,239)7,713–68,629
1,682,2102311,756,280
a) 18,895,000184,815,0006,798,00014.45VIVO
OPPORTUNITY FUND L.P.GAOLING FUND L.P.YHG INVESTMENT, L.P.b) A264,648,2170.00000211.03
2,919,070,000
┃
32.
(a)
i. 10%ii. King Bridge6.59
(b)
33.
A0.000002AB0.000002B
┃
33.
10183,888,050B
1022,200,000B
1068,498,464B
10%10%
┃
33.
0.126137,5710.051162,851
0.17802,7000.148713,241
0.1133(2,725)0.0297(7,350)
0.0825(7,713)0.0071(31,171)
0.143329,8330.126137,571
1.20281.7236
3,2250.0000021-10-202-9-312,4750.05516-3-2215-9-3124,1330.1782-8-2015-9-32
29,833
7,9890.0000021-11-1815-9-313,0000.05530-9-2015-9-3126,5820.1782-8-207-10-3137,571
┃
33.
(%)42.68-46.5743(%)2.19-3.421.33-1.63
1010
1.2690-1.40152.3591-2.8699
126.4
129.5
52,278,537
2.96%
34.
(a)
9,542,0009,542,00058,694,00058,694,00049,217,0004,965,000
┃
34.
(b)
–1,200,56437,69367,7781,306,035––324,441(24,478)299,963453,239(3,396)––449,843––(84,788)–(84,788)–––7878–––9,5429,542–––(73)(73) 6,278–10,4152,70419,397
459,5171,197,168287,76155,5511,999,997
1,149,550–23,9981,173,548
–50,000(17,445)32,55551,014––51,014–(12,420)–(12,420)––(29)(29)––58,69458,694–1132,5602,6731,200,56437,69367,7781,306,035
┃
34.
(c)
1,94381024,47817,445
26,42118,255
35.
325,000,000142936.
130,95661,464
201555
BTKBTKBTK(1)
(2)BTKBTK
BTK
┃
37.(a)
23,30619,45525232059,39762,527
82,95582,302
(b)
Beijing Baiaozhihui Technology Co., Ltd.
Beijing BaiaozhihuiDimi Biological Medicine Technology
(Shanghai) Co., Ltd.DimaiVivo Opportunity Fund, L.P.
VivoOpportunity Co-Invest, L.P.
5%
┃
37.(c)
(i)507642 (ii)–33,159 Beijing Baiaozhihui–73 Dimai–6
50733,880
(iii)134–
20,000–
(i)(ii)(iii)(iv)
(v)
(vi) Vivo Opportunity Fund, L.P.Vivo Opportunity Co-Invest, L.P.14.45
18,895,000
┃
37.
(d)
134–
– 20,000 117252
11720,252
┃
38.
127,825–127,825
–313,290313,290
49,640–49,640
8,697,927–8,697,927
8,875,392313,2909,188,682
118,597–118,597287,761–287,761
637,959–637,959
–1,197,1681,197,168
1,044,3171,197,1682,241,485
┃
38.
45,273–45,273–621,734621,734 44,911–44,911
5,928,716–5,928,7166,018,900621,7346,640,634
84,602–84,60237,693–37,693 96,178–96,178
–1,200,5641,200,564218,4731,200,5641,419,037
┃
39.
–313,290–313,290
–621,734–621,734
┃
39.
––1,197,1681,197,168
––1,200,5641,200,564(i)
(%)
1,197,1682.15~4.301,200,5642.45~4.60
┃
39.
(i)
2.15%
1%(11,430)/11,652
2.45%
1%(34,381)/35,746
2.15%
1%(8,533)/8,698
2.15%
1%(4,805)/4,992
┃
40.
%
55,237
(5)(5,237)
5191
(5)(191)
52,245
(5)(2,245)
5923
(5)(923)
┃
40.
–––127,825127,825
49,640–––49,640
8,697,927–––8,697,927
8,747,567––127,8258,875,392
–––45,27345,27344,911–––44,9115,928,716–––5,928,7165,973,627––45,2736,018,900
┃
40.
118,597––118,597 654,778––654,778
23,82237,799–61,621
1,138379,856–380,994a1,242,325––1,242,325
2,040,660417,655–2,458,315
84,602––84,602 96,178––96,178
22,68750,646–73,333
–50,875–50,875a–1,302,775–1,302,775
203,4671,404,296–1,607,763
(a)
┃
40.
287,76137,6931,197,1681,200,564
459,517–
1,944,4461,238,257
10,321,1587,397,531
19%17%
┃
41.
2,450,5091,590,0036,970,0684,705,28241,20153,256
9,461,7786,348,541
12,9442,953
12,9442,953
9,448,8346,345,588
9,448,8346,345,588
9,448,8346,345,588
23199,448,8116,345,569
9,448,8346,345,588
9,371,725602260,235(515,562)(2,771,431)6,345,569––––(392,089)(392,089)–––591,944–591,944
–––591,944(392,089)199,855A2,919,066––––2,919,066
(149,440)––––(149,440)
––129,477––129,47768,629–(64,345)––4,284
12,209,980602325,36776,382(3,163,520) 9,448,811
┃
41.
6,743,235602234,183(405,261)(2,769,771)3,802,988––––(1,660)(1,660)–––(110,301)–(110,301)–––(110,301)(1,660)(111,961)2,526,672––––2,526,672––126,444––126,444101,818–(100,392)––1,4269,371,725602260,235(515,562)(2,771,431)6,345,56942.
MSBTK
43.
2022ESG
1.
1.1216
1.2ESG219
1.32212.
2.1223
2.2224
2.32263.
3.1229
3.2233
3.3237
4.1239
4.2241
4.32435.
5.1248
5.2248
5.3250
5.4252
6.
6.1254
6.22567.
7.1258
7.2259
7.3260
8.2619.
1(2022)
2272
┃
09969.HK688428.SH
20221120221231
20221
┃
?
?
?
?
ESG
(www.innocarepharma.com)(www.hkexnews.hk)http://www.sse.com.cn/
Emailir@innocarepharma.com
┃
1.
1.1
20159969.HK688428.SH
┃
1.
2022?
?? CD20xCD3ICP-B02
?? II
? II??? TYK2 JH2ICP-488? RTKICP-033
? 2022(AACR)ICP-723? 2021? ICP-490
? 2022? Tafasitamab(NMPA)II
┃
1.
? 2022(EULAR)? 2022(ASCO)? TafasitamabDLBCL(CSCO)? PD-1PCNSL2022(EHA)? 16? CCR8ICP-B05? SHP2ICP-189
?? ICP-490(MM)
(NHL)? BCL2ICP-248? TafasitamabDLBCL
? TYK2 JH2ICP-488?? CCR8ICP-B05? TafasitamabDLBCL
? RCHOPnon-GCBDLBCL2022
(ESMO)
? (NMPA)(CDE)BTK
(MZL)? TafasitamabDLBCL II? BCL2ICP-248? H+A
┃
1.
? Tafasitamab? eClinicalMedicineII? 2022? TRKICP-723
? TafasitamabB? 1064(ASH)?
?
(HSA)(R/RMCL)
? 2022· 21? TafasitamabB? 2022? 2022? IPO? 2021? 2022TOP100
1.2 ESG
ESGESGESG
ESGESGESGESG
┃
1.
ESG
ESG? ESG? ESG? ESGESGESGESG
? ESG? ESG? ESG? ESG? ESG? ESGESG2022ESGESG
ESGESGESGESGESG2022122022
┃
1.
1.3
ESGESG
ESGESG
???
????????
???????
??????
????
????
????
?
?
?
?
?
┃
1.
ESG
ESG?
ESG
??
??
┃
2.
2.1
2022
202210
2022
┃
2.
2.2
HA
2022621
┃
2.
(www.hkexnews.hk)(www.innocarepharma.com)2022
A
2022H+A
IPOIR
┃
2.
2.3
EHS
┃
2.
EHS
EHSEHS
EHS
┃
2.
MRP43
EHS
2022
┃
3.
3.1
2015
CMC2022NMPA
BTK
┃
3.
CMC
CRO
43043.8%2022
first-in-classCM369
CCR8CM369Tafasitamab1330
┃
3.
2022
NDA
IND Enabling
PH3PHIaPH2*
Filed
PHIbPH2**
Market
ICP-B05
pan-FGFRpan-TRKICP-192/GunagratinibICP-723/Zurletrectinib
VEGFR, DDR1ICP-033
SHP2ICP-189CCR8
BTK
TYK2 –JH1
TYK2 –JH2
ICP-022/OrelabrutinibICP-332ICP-488
NDA
INDEnabling
PH3PHIaPH2*
Filed
PHIbPH2**
Market
ICP-022/Orelabrutinib
BTKr/rWMr/rCLL/SLLr/rMCLr/rMZL
ICP-B02CD3xCD20
ICP-248NHL/ALL/BCL-2
ICP-490
MM/DLBCL/E3Ligase
1L:CLL/SLL
Tafa+LEN,r/rDLBCL
r/rMCL
1L:MCL
ICP-B04/Tafasitamab
CD19
1L:MCDDLBCL
HKTafa+LEN+OrelaNHL
CHN,SG
CHN
CCR8ICP-B05Hemato-oncology
┃
3.
202220222022
2021
(GCP)SOP
(GB/T 35892-2018)(IACUC)
┃
3.
2022
27554
??
?
?
3.2
(GMP)(GCP)(GLP)
(ICH)
┃
3.
(FMEA)(HACCP)
GMPCAPA2022
(Qualified Person)MAH
GLP
(ICH-GCP)
┃
3.
QAMAH
CAPA
┃
3.
50mg
(400-635-1999)(PV@innocarepharma.com)
(PV)
┃
3.
3.3
202211???? IDC??????
┃
3.
(info@innocarepharma.com)(400-635-1999)
20228100%
┃
4.
4.1
┃
4.
? 2022???? 101215
22025? 2022
┃
4.
??? HR????????
4.2
┃
4.
100%202211
ExcelOrientation
CEO
2023320188
1,110,0007610,000
┃
4.
4.3
EHSEnvironment, Health andSafetyEHSEHSEHSEHSEHS565EHSISO 45001
EHSEHSEHSCEO
EHS2022EHS
EHS
┃
4.
EHS
112022EHS002022EHSQCQC
202237260
2022EHS
┃
4.
?
2022382?202229?
202226?
2022 6? EHS2022
1,0832022
100%
┃
4.
2022EHS&MARATHON2022621
5100%
┃
4.
2022520222,707,806
┃
5.
5.1
ISO 140012022
2022
2021ESG
5.2
┃
5.
2620
EHS
┃
5.
5.3
2016
??? (COD)(BOD)??
┃
5.
????????????
┃
5.
5.4
·(Task Force onClimate-related Financial Disclosures, TCFD)
??
? ? ESG
?
┃
5.
┃
6.
6.1
ISO 37301
2022
(www.innocarepharam.com)
┃
6.
202217
2022
2022
(www.innocarepharam.com)
legal_compliance@innocarepharma.com
8102206
┃
6.
6.2
┃
6.
EHSEHS
┃
7.
7.1
2022
2022(AACR)TRKICP-7232022(EULAR)
(BTK)
2022(ASCO)
? FGFR 1-4gunagratinib (ICP-192)FGF/FGFRI? TRKICP-723
(PK)? B2022(EHA)
PD-1(PCNSL)II
┃
7.
2022(ESMO)
RCHOPnon-GCBB(DLBCL)2022 ESMO
64(ASH)
(BTK)10ASH? (HD-MTX)
(PCNSL)? III
R-CHOPR-CHOPMCDB? PD-1
I/II? RCHOPB
7.2
202211(HSA)(R/R MCL)20227tafasitamab Minjuvi
?
DLBCLTafasitamab18Btafasitamab
2021
tafasitamab
┃
7.
2022Tafasitamab2022(CSCO)(ASCT)B(DLBCL)IICSCO
7.3
2022
202231
23.7
2022
? CEO
??? 2021? 16? 2022
┃
8.
202262,540.4(0.63)
0.25
1 =+++
2020202120221,991.108,667.3010,820.952,895.169,894.909,380.31
6.4113.729.5656,311.00145,093.00124,940.00
124.58201.24127.36
0.000.751.8
0.0010.002
82,84399,527(COD)2,4691,396(BOD)417381(NH
-N)8229
37,180,000(VOC)23.62
270.86
49.06
14.3
1,926.002,874.541,074.10
30.10106.79115.05
4.263.991.09
0.070.150.12
┃
8.
202020212022
CO
2,476.599,236.409,835.80
CO
CO
2,476.599,236.409,835.80CO
5.4812.8110.03
202152 03 20232025
20210.61010.57032019200820200.11
0.128620202021
202020212022
452721981234350457218371524448698939
41321010213017623033230-5026047262850161921
44470796781414
581806134169
┃
8.
202020212022
%15.2613.76%11.0014.5715.32%7.0015.9012.4030%15.0016.5218.9830-50%13.0014.4111.31
%0.0021.054.76%9.0015.2813.75%0.0014.2914.29
%000
%100.00100.00100.00%100.00100.00100.00%100.00100.00100.00%100.00100.00100.00%100.00100.00100.00%100.00100.00100.00
10.0025.0028.20
10.0030.0028.43
8.0021.0028.01
8.0019.0022.30
12.0053.0056.26
18.0030.0030.83
┃
8.
1 =*100%2 2021502021/2022503 =*100%4 =
202020212022500587722488575687
121235
┃
8.
202020212022
%0.000.000.00
202020212022
100.00100.0076.80
18.40
50.00
8.40
┃
8.
202020212022
172648920
0.190.450.61
%022.2233.33
00.220.67
1 2022
202020212022402,711721,58464,489%2956999
193286418%48.246.946.4%37.836.438.5%12.414.312.2
1718
2252753754
┃
9.
A3.5.1A3.1
5.15.2
5.3
A4.5.4A4.15.4B.B1.4.1B1.1B1.2B2.4.3B2.1B2.2B2.34.3
A.A1.5.3A1.1
5.15.3
A1.2A1.3A1.4A1.5
5.15.3
A1.6
5.15.3
A2.5.2A2.1A2.2A2.3
5.15.2
A2.4
5.15.2
A2.5
┃
9.
B3.4.2B3.1B3.2B4.4.1B4.14.1B4.2B5.6.2B5.1B5.26.2B5.36.2B5.46.2B6.3.2B6.1B6.23.3
B6.33.1B6.43.2B6.53.3B7.6.1B7.1
6.1
B7.26.1B7.3
6.1
B8.
7.27.3
B8.1
7.27.3
B8.2
┃
9.
1(2022)
8.1
1.2 ESG2.12.2
3.23.34.1
5.16.27.3
8.21.2 ESG3.16.1
8.31.2 ESG
8.4
8.5
1.2 ESG3.2
4.15.17.2
7.3
8.6
8.6
8.6
8.72.14.1
8.85.1
8.85.1
8.85.2
8.85.3
8.85.3
8.85.1
8.86.2
8.85.1
┃
9.
8.95.1
8.9
8.95.1
8.95.15.3
8.95.1
8.95.3
8.9
8.9
8.9
5.15.25.3
5.4
8.10
8.10
8.10
8.10
8.10
8.10
┃
9.
8.115.1
8.12
5.3
2022
8.12
5.15.25.3
8.125.1
8.125.3
8.133.2
8.133.2
8.133.2
8.136.2
8.144.1
8.144.3
8.144.2
8.14
4.14.24.3
8.153.1
┃
9.
-13.1-23.1-33.1-43.1-1
5.15.25.3
-2
4.14.24.3-3
3.23.36.1
7.27.3
-4
2.12.22.3
2022年度報告
InnoCare Pharma Limited
諾誠健華醫藥有限公司
SCIENCE DRIVESINNOVATIONFOR THE BENEFIT OF PATIENTS科學驅動創新
患者所需為本